Highlights Vaxcyte, Inc.

Stocks

PCVX

US92243G1085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 13/06/2026 am IST			5-day change	1st Jan Change
47.46 ^USD	+0.36%		+0.21%	+2.86%

03/06	Vaxcyte Doses First Participant in Phase 1 Trial of Group A Strep Vaccine Candidate VAX-A1	MT
03/06	Vaxcyte Doses First Participant In Phase 1 Study Evaluating VAX-A1 For The Prevention Of Disease Caused By Group A Streptococcus In Healthy Adults	CI

Highlights

03/06	Vaxcyte Doses First Participant In Phase 1 Study Evaluating VAX-A1 For The Prevention Of Disease Caused By Group A Streptococcus In Healthy Adults	CI
07/05	Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
23/03	Vaxcyte Inc Completes Enrollment Of OPUS-1 And OPUS-2 Phase 3 Trials Evaluating VAX-31 For The Prevention Of Invasive Pneumococcal Disease And Pneumonia In Adults	CI
19/03	Vaxcyte, Inc. Publishes Positive Phase 1/2 Adult Data For VAX-31 Pneumococcal Conjugate Vaccine Candidate	CI
25/02	Vaxcyte Q4 Loss Widens	MT
25/02	Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12/02	Vaxcyte, Inc. Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines	CI
03/02	Vaxcyte Closes Public Offering of Shares	MT
30/01	Vaxcyte Launches $500 Million Public Offering	MT
23/01	Vaxcyte, Inc. Advances Adult and Infant Programs for VAX-31, a Potential Best-In-Class, Next-Generation Pneumococcal Conjugate Vaccine	CI
08/12	Vaxcyte, Inc. Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults	CI
05/11	Vaxcyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
01/25/01	Vaxcyte, Inc. to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services	CI
30/25/30	Vaxcyte to Expand Fill-Finish Manufacturing Capacity in US; Shares Up Pre-Bell	MT
03/25/03	Vaxcyte, Inc. Advances VAX-31 Infant Phase 2 Dose- finding Study with First Participants Receiving VAX-31 Optimized Dose	CI
07/25/07	Vaxcyte, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
08/25/08	Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
31/25/31	Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study	CI
26/25/26	Vaxcyte 2024 Loss Narrows	MT
26/25/26	Earnings Flash (PCVX) Vaxcyte 2024 Loss Per Share $-3.80 vs. FactSet Est Loss of $-4.16	MT
26/25/26	Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
05/25/05	Vaxcyte, Inc. Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for Prevention of Invasive Pneumococcal Disease in Infants	CI
03/24/03	Vaxcyte, Inc. Initiates Phase 2 Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Infants	CI
22/24/22	Vaxcyte, Inc. Announces Amended and Restated the Original Lease and Enters into Sublease Agreement with Iovance Biotherapeutics, Inc	CI
12/24/12	Vaxcyte, Inc. Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs	CI